Genmab — September 2018

[Jazzz]

Som aktionær kunne jeg godt ha tænkt mig at ledelsen havde ventet med at annoncere deres “nye” strategi, indtil efter MAIA data forelå. Det ville ha givet os en chance for at vurdere om man så vil ud af aktien, inden den næste pipeline bølge skulle diskuteres.

[JørgenVarnæs]

Det håber jeg dælme også. Jeg bliver nemlig snart sur

[lahn1]

Bliver ?

[lahn1]

[mobbyduck1]

Jeg kan ikke rigtig se ideen med disse kapitalmarkeds dage, de sidste to år, har kursen fået tæsk i dagene efter, specielt efter Davids hjerneblødning forrige år, burde man være lidt klogere. Timningen sidder ihvertfald ikke i skabet

[Helge_LarsenPI-redaktør]

JV..Du kan da glæde dig over "obligationsaspektet" .

[Bulder]

kan hurtigt blive aktuelt

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[E_L]

early bird Sukkeralf…

[E_L]

this Dara SC trial re-opened for recruiting an extra 30 patients https://clinicaltrials.gov/ct2/history/NCT02519452?A=30&B=31&C=merged

[E_L]

If I am correct they are trying to see if they can do without corticosteroids??

[Solsen]

Isnt it the old PAVO study opened again. I would guess its the "Dara-CF" thats could be a new formulation. A good question to JW in a Q&A on PI.

[Bulder]

It's the original PAVO study. And yes it looks like they've made a part 3 - non-dex - with 30 pts.

[Bulder]

And it seems to be 2 sites in Spain that have reopened recruitment.

[Solsen]

You are both are right its described in "Study Description"

[Solsen]

They are optimistic about the sideeffect by trying without dex.

[Bulder]

And it's going to be very popular among pts and their relatives.

[Solsen]

The dara-cf sc is very important like MAIA is to the potential of dara. I would say crucial !

[E_L]

yes. and i am wondering if we can do without corticosteroids, if that would give a change on the effect with PD(L)1 on solids

[Bulder]

Winkel said that it was necessary to give dex to these very ill nsclc pts.